Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations
New England Journal of Medicine, 2022•Mass Medical Soc
Bedaquiline-Resistant Tuberculosis in South Africa Bedaquiline use began in 2015 in South
Africa to treat drug-resistant tuberculosis. A non–target-based mutation in the mmpR
(Rv0678) gene encoding an efflux pump repressor has been identified in the majority of
bedaquiline-resistant isolates over the past 5 years.
Africa to treat drug-resistant tuberculosis. A non–target-based mutation in the mmpR
(Rv0678) gene encoding an efflux pump repressor has been identified in the majority of
bedaquiline-resistant isolates over the past 5 years.
Bedaquiline-Resistant Tuberculosis in South Africa
Bedaquiline use began in 2015 in South Africa to treat drug-resistant tuberculosis. A non–target-based mutation in the mmpR (Rv0678) gene encoding an efflux pump repressor has been identified in the majority of bedaquiline-resistant isolates over the past 5 years.
The New England Journal Of Medicine